Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris

1995 ◽  
Vol 49 (1-2) ◽  
Author(s):  
K. Boman ◽  
L.G. Karlsson ◽  
H. Saetre ◽  
B. Ritter ◽  
R. Marsell ◽  
...  
Keyword(s):  
Controlled Release ◽  
Angina Pectoris ◽  
Stable Angina ◽  
Stable Angina Pectoris ◽  
Antianginal Effect

Long-Term Efficacy of Diltiazem Controlled Release Versus Metoprolol in Patients with Stable Angina Pectoris

1991 ◽  
Vol 18 ◽  
pp. S55-S60
Author(s):  
H. W. Vliegen ◽  
E. E. van der Wall ◽  
M. G. Niemeyer ◽  
N. J. Holwerda ◽  
P. J. L. M. Bernink ◽  
...  
Keyword(s):  
Controlled Release ◽  
Angina Pectoris ◽  
Stable Angina ◽  
Stable Angina Pectoris ◽  
Term Efficacy

Long-Term Efficacy of Diltiazem Controlled Release Versus Metoprolol in Patients with Stable Angina Pectoris

1991 ◽  
Vol 18 ◽  
pp. S55-S60 ◽  
Author(s):  
H. W. Vliegen ◽  
E. E. van der Wall ◽  
M. G. Niemeyer ◽  
N. J. Holwerda ◽  
P. J. L. M. Bernink ◽  
...  
Keyword(s):  
Controlled Release ◽  
Angina Pectoris ◽  
Stable Angina ◽  
Stable Angina Pectoris ◽  
Term Efficacy

scholarly journals Cliniko-experimental research of trimetazidine efficiency at the myocardium ischemia

2013 ◽  
Vol 4 (2) ◽  
pp. 43-47
Author(s):  
O. V Romashchenko
Keyword(s):  
Experimental Data ◽  
Angina Pectoris ◽  
Experimental Research ◽  
Stable Angina ◽  
Tissue Hypoxia ◽  
Physical Working Capacity ◽  
Working Capacity ◽  
Stable Angina Pectoris ◽  
Energy Deficiency ◽  
Antianginal Effect

The randomized controllable clinical research of Trimetazidine (Preductal MB) efficiency was spent at 95 patients with a stable angina pectoris. There were revealed the authentic increase in 2 times of treatment’s clinical efficiency in patients, who in addition to basic therapy appointed Trimetazidine for the account of more expressed antianginal effect and increase of physical working capacity. Additional appointment of Trimetazidine at a myocardium ischemia promoted the reduction of energy deficiency and tissue hypoxia. Last position has proved to be true according to experimental data: at rats males of line Vistar at experimental IHD the introduction of Trimetazidine led to increase of recycling of carbohydrates with the power purposes in a cardiac muscle that was accompanied by signs of stabilisation of cardiomyocytes’ membranes and reduction of degree of tissue hypoxia.

scholarly journals Comparison of Diltiazem Standard Formulation and Diltiazem Controlled Release in Patients with Stable Angina Pectoris

1993 ◽  
Vol 21 (4) ◽  
pp. 552-559 ◽  
Author(s):  
H. W. Vliegen ◽  
E. E. van der Wall ◽  
J. A. Kragten ◽  
N. J. Holwerda ◽  
W. M. Schenkel ◽  
...  
Keyword(s):  
Controlled Release ◽  
Angina Pectoris ◽  
Stable Angina ◽  
Standard Formulation ◽  
Stable Angina Pectoris

Modulation of Plasma Fibrinogen Levels by Ticlopidine in Healthy Volunteers and Patients with Stable Angina Pectoris

1996 ◽  
Vol 76 (02) ◽  
pp. 166-170 ◽  
Author(s):  
Moniek P M de Maat ◽  
Alf E R Arnold ◽  
Stef van Buuren ◽  
J H Paul Wilson ◽  
Cornells Kluft
Keyword(s):  
Angina Pectoris ◽  
Healthy Volunteers ◽  
Acute Phase ◽  
Stable Angina ◽  
Gene Polymorphisms ◽  
Acute Phase Reaction ◽  
Plasma Fibrinogen ◽  
Phase Reaction ◽  
Stable Angina Pectoris ◽  
Lowering Effect

SummaryElevated plasma fibrinogen levels are associated with an increased risk for cardiac events. Ticlopidine is a drug that inhibits the ADP-induced aggregation of blood platelets and it also has been described that ticlopidine can decrease the plasma fibrinogen level in patients with vascular diseases. The mechanism of this decrease has not yet been elucidated and therefore mechanisms that are known to affect fibrinogen levels were studied, viz. the acute phase reaction, total fibrin plus fibrinogen degradation (TDP) levels and the polymorphisms of the fibrinogen β-gene.The fibrinogen lowering effect of ticlopidine was studied in 26 healthy volunteers, selected on genotype of the BclI polymorphism of the fibrinogen β-gene, and in 26 patients with stable angina pectoris in a double blind, randomized cross-over study. Functional plasma fibrinogen levels were measured with the Clauss assay. Fibrinogen antigen, C-reactive protein (CRP) and TDP levels were measured using an enzyme immuno assay (EIA).In the healthy volunteers the functional fibrinogen levels had decreased by 0.20 g/l (9%, p = 0.005 using the paired Student t-test) after 4 weeks of 250 mg bid ticlopidine administration, whereas fibrinogen antigen, CRP and TDP levels were not significantly changed. In the stable angina pectoris patients the pre-treatment fibrinogen, CRP and TDP levels were significantly higher than in the volunteer group. After four weeks 250 mg bid ticlopidine administration the functional fibrinogen levels had decreased by 0.38 g/l (11%, p < 0.005), whereas the fibrinogen antigen, CRP and TDP levels were not significantly changed. The levels of functional and antigen fibrinogen, CRP and TDP did not change significantly during the placebo period in the volunteers or the patients. Neither in the volunteers nor in the patients was the effect of ticlopidine on the fibrinogen levels associated with the fibrinogen β-gene polymorphisms.Therefore, the fibrinogen lowering effect of ticlopidine is likely to be a modulation of the functionality of the molecule and unlikely to be modulated by the acute phase reaction, TDP-levels or the fibrinogen β-gene polymorphisms.

Sign in / Sign up

Export Citation Format

Share Document